Wide Ranks

CYTO

Altamira Therapeutics Ltd.

0.4025

Top Statistics
Market Cap 1 M Forward PE -0.3440 Revenue Growth 0.00 %
Current Ratio 0.43 Trailing PE 0.2212 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 65455 Total Cash Per Share 0.0250 Total Debt 427437
Total Debt To Equity 6.76 Current Ratio 0.43 Book Value Per Share 2.37
All Measures
Short Ratio 108.00 % Message Board Id finmb_42726152 Shares Short Prior Month 11575
Return On Equity -3.69 City Hamilton Uuid 73e41d6d-d768-3dba-b766-fc7bbc4c1528
Previous Close 0.4215 First Trade Date Epoch Utc 1 B Book Value 2.37
Beta 2.44 Total Debt 427437 Volume 56616
Price To Book 0.1701 Last Split Date 1 B Fifty Two Week Low 0.4000
Total Cash Per Share 0.0250 Shares Short Previous Month Date 1 B Target Median Price 4.50
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 4.50
Net Income To Common -7906370 Short Percent Of Float 0.0280 Implied Shares Outstanding 3 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 161890
Average Volume10days 161890 Total Cash 65455 Next Fiscal Year End 1 B
Held Percent Insiders 0.0053 Trailing PE 0.2212 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.4215 Target Low Price 4.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.5492 Open 0.4215
Free Cashflow -5412231 Dividend Yield 0.00 % Return On Assets -0.5715
Time Zone Short Name EST Trailing Eps 1.82 Day Low 0.4000
Address1 Clarendon House Shares Outstanding 3 M Price Hint 4
Target High Price 4.50 Website https://altamiratherapeutics.com 52 Week Change -0.9485
Average Volume 75534 Forward Eps -1.34 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 15.20 % Last Split Factor 1:20
Regular Market Day High 0.4349 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 6.76 Fifty Two Week High 17.20 Day High 0.4349
Shares Short 105412 Regular Market Open 0.4215 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0279
Operating Cashflow -7582773 Currency USD Time Zone Full Name America/New_York
Market Cap 1 M Is_nasdaq_100 False Zip HM 11
Quote Type EQUITY Industry Biotechnology Long Name Altamira Therapeutics Ltd.
Regular Market Day Low 0.4000 Held Percent Institutions 0.0314 Current Price 0.4025
Address2 2 Church Street Financial Currency USD Current Ratio 0.43
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country Bermuda
Float Shares 2 M Two Hundred Day Average 1.21 Enterprise Value 1 M
Forward PE -0.3440 Regular Market Volume 56616 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Altamira Therapeutics Ltd.

operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia.

The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues.

Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.

It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens.

The company was formerly known as Auris Medical Holding Ltd.

and changed its name to Altamira Therapeutics Ltd.

in July 2021.

The company was founded in 2003 and is based in Hamilton, Bermuda.